Heartbeam Inc Stock Price, News & Analysis

HeartBeam (NASDAQ: BEAT) has secured two new U.S. patents, strengthening its intellectual property portfolio in cardiac monitoring technology. The first patent protects their credit card-sized, cable-free 3D ECG device with chest and finger electrodes that capture high-fidelity electrical signals in three non-coplanar directions. The second patent covers their rhythm analysis algorithm for distinguishing between various heart rhythms using continuous signal input, designed for integration with wearable devices.

The company's 12-lead ECG synthesis software is currently under FDA review, supported by data from the VALID-ECG pivotal study presented at the Heart Rhythm Society conference in April 2025. HeartBeam now holds 20 issued patents worldwide, with 2 allowed patents and 32 pending patents, positioning itself as a leader in cardiac monitoring innovation.

HeartBeam (NASDAQ: BEAT) has appointed CEO Robert Eno to its Board of Directors, expanding from eight to nine members. Eno, who joined as President in January 2023 and became CEO in October 2024, brings over 30 years of medical technology industry experience. The company received FDA clearance for its 3D ECG technology in December 2024 and submitted an FDA application for its 12-lead ECG synthesis software in January 2025.

HeartBeam's technology captures heart electrical signals in 3 non-coplanar directions and synthesizes them into a 12-lead ECG. The company has initiated an Early Access Program to gather feedback on clinical workflow and establish early adopters. Prior to HeartBeam, Eno served as CEO of Preview Medical and held leadership roles at HeartFlow, OptiMedica, NeoGuide Systems, and Avantec Vascular.

HeartBeam (NASDAQ: BEAT) has announced its upcoming first quarter 2025 earnings conference call, scheduled for Tuesday, May 13, 2025, at 4:30 p.m. Eastern time. The call will be hosted by CEO Robert Eno and CFO Timothy Cruickshank, who will discuss Q1 2025 results, regulatory initiatives, commercial-readiness activities, and anticipated milestones. A detailed press release will be issued before the call.

The conference call will include a presentation accessible during the webcast and afterward through the company's investor relations website. A replay will be available for three months until August 13, 2025, through both domestic (1-844-512-2921) and international (1-412-317-6671) dial-in numbers.

HeartBeam has achieved a significant breakthrough in cardiac care technology, announcing successful clinical endpoints in its VALID-ECG pivotal study for its synthesized 12-lead ECG technology. The study, presented at the Heart Rhythm Society's conference in San Diego, demonstrated a 93.4% overall diagnostic agreement with standard 12-lead ECGs for arrhythmia assessment.

The company's innovative solution uses a credit card-sized device featuring patented 3D ECG technology that captures heart electrical signals in 3 non-coplanar directions. These signals are then transformed into a 12-lead ECG using a personalized matrix.

Key highlights:

• FDA application submitted in January 2025 for the 12-lead ECG synthesis software
• Early Access Program launched to gather clinical workflow feedback
• Multicenter trial conducted across 5 major US clinical sites with 198 patients
• Participating institutions include Allegheny Health Network, Mount Sinai Hospital, and Piedmont Heart Institute

The company plans to begin commercialization upon receiving FDA clearance.

HeartBeam (NASDAQ: BEAT) has announced a strategic collaboration with AccurKardia to advance cardiac monitoring innovation. The partnership will integrate AccurKardia's FDA-cleared ECG analysis software, AccurECG™, into HeartBeam's devices.

HeartBeam's innovative technology features a credit card-sized, cable-free 3D ECG device that captures heart signals in 3 non-coplanar directions and converts them into a 12-lead ECG using a personalized transformation matrix. The company plans to begin commercialization after receiving FDA clearance for the 12-lead ECG synthesis software.

The collaboration aims to enhance cardiac monitoring accessibility by combining HeartBeam's device with AccurKardia's automated ECG interpretation platform, enabling faster diagnosis and improved access to clinical care. This partnership is expected to accelerate HeartBeam's product development while reducing costs and timelines.

HeartBeam (NASDAQ: BEAT) reported its Q4 and full year 2024 results, marking significant milestones in cardiac care technology. The company received FDA 510(k) clearance for its HeartBeam System for arrhythmia assessment and launched an Early Access Program. They also submitted a 510(k) application for their 12-lead ECG synthesis software.

Financial highlights include securing $11.5 million in gross proceeds from a public offering. Q4 2024 showed R&D expenses of $2.9M (vs $2.0M in Q4 2023) and G&A expenses of $2.1M. The company reported a net loss of $4.9M for Q4 2024 and $19.4M for the full year. Cash position stood at $2.4M as of December 31, 2024.

Clinical progress includes presenting positive results at the American Heart Association conference, demonstrating comparable performance between HeartBeam's synthesized 12-lead ECG and standard ECGs for arrhythmia detection.

HeartBeam (NASDAQ: BEAT), a cardiac care medical technology company, has announced its participation in two major conferences in Dana Point, California during March 2025. CEO Robert Eno and CFO Timothy Cruickshank will attend:

• The 37th Annual Roth Conference at The Laguna Cliffs Marriott Resort & Spa from March 16-18, 2025
• The LSI USA '25 Conference at the Waldorf Astoria, Monarch Beach from March 17-21, 2025

Investors interested in one-on-one meetings with HeartBeam management can arrange appointments through their conference representatives or by contacting BEAT@mzgroup.us.

HeartBeam (NASDAQ: BEAT), a medical technology company specializing in cardiac care through personalized insights, has scheduled its Q4 and Full Year 2024 earnings conference call for March 13, 2025, at 4:30 p.m. Eastern time.

The call will feature CEO Robert Eno and CFO Timothy Cruickshank, who will discuss financial results, provide updates on regulatory initiatives, commercial-readiness activities, and anticipated milestones. A detailed press release will be issued before the call, and a presentation will be available during the webcast and afterward through the company's investor relations website.

HeartBeam (NASDAQ: BEAT) has successfully completed the over-allotment option of its public offering, with the underwriter purchasing an additional 864,033 shares at $1.70 per share, generating approximately $1.5 million in additional gross proceeds. This follows the firm commitment underwritten offering of 5,882,353 shares that closed on February 14, 2025.

The total offering now comprises 6,746,386 shares with gross proceeds of approximately $11.5 million. MDB Capital acted as the underwriter, with Paulson Investment Company participating as a selected dealer. The over-allotment option closed on February 25, 2025.

The company plans to utilize the net proceeds for:

• Commercial-readiness activities
• Investments in R&D, clinical, and regulatory projects
• Working capital
• General corporate purposes